Page last updated: 2024-10-15

nolatrexed

Description

nolatrexed: structure given in first source; RN given refers to dihydrochloride [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135400184
CHEMBL ID320775
SCHEMBL ID18489
MeSH IDM0260396

Synonyms (41)

Synonym
bdbm50046657
2-amino-6-methyl-5-(pyridin-4-ylsulfanyl)-3h-quinazolin-4-one
NCI60_016753
nsc648316
2-amino-6-methyl-5-(4-pyridylsulfanyl)quinazolin-4-ol
2-amino-6-methyl-5-(4-pyridinylthio)-4-quinazolinol hydrochloride
nolatrexed
CHEMBL320775 ,
2-amino-6-methyl-5-pyridin-4-ylsulfanyl-1h-quinazolin-4-one
k75zun743q ,
nolatrexed [inn]
unii-k75zun743q
2-amino-6-methyl-5-(4-pyridylthio)-4(3h)-quinazolinone
2-amino-6-methyl-5-(4-pyridylthio)-4(3h)-quinazolinone.
147149-76-6
SCHEMBL18489
nolatrexed [who-dd]
nolatrexed [mart.]
nolatrexed [mi]
2-amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)quinazoline
2-amino-6-methyl-5-(4-pyridinylthio)-4(1h)-quinazolinone
DTXSID3048281
nolatrexed (ag-337)
AC-25494
AKOS025401776
7z9 ,
2-azanyl-6-methyl-5-pyridin-4-ylsulfanyl-3h-quinazolin-4-one
2-amino-6-methyl-5-pyridin-4-ylsulfanyl-3h-quinazolin-4-one
NCGC00181023-04
2-amino-6-methyl-5-(pyridin-4-ylsulfanyl) -3h-quinazolin-4-one
DB12912
'nolatrexed; 2-amino-6-methyl-5-(4-pyridylthio)-1h-quinazolin-4-one'
2-amino-6-methyl-5-(4-pyridylthio)-1h-quinazolin-4-one
FT-0712501
2-amino-6-methyl-5-(pyridin-4-ylthio)quinazolin-4(3h)-one
BCP12638
Q7048249
HMS3744I03
NCGC00181023-03
TQR1204
NCGC00181023-02

Pharmacokinetics

ExcerptReference
"To establish the maximum tolerated dose (MTD), dose-limiting and other major toxicities and the major pharmacokinetic parameters of a 10-day infusion of the nonclassical antifolate Thymitaq."( Initial clinical trial and pharmacokinetics of Thymitaq (AG337) by 10-day continuous infusion in patients with advanced solid tumors.
Clendeninn, NJ; Creaven, PJ; Dixon, M; Johnston, A; Loewen, GM; Meropol, NJ; Pendyala, L; Proefrock, A; Wu, EY, 1998
)
" The aims were to optimize the schedule of administration and determine any pharmacokinetic (PK) interactions between the two drugs."( Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel.
Boddy, AV; Calvert, AH; Griffin, MJ; Hughes, AN; Johnston, A; Kerr, B; Lee, C; Liang, B; Newell, DR, 2000
)

Bioavailability

The absolute bioavailability of nolatrexed dihydrochloride in mice was 23. This provides an experimental basis for development of the oral preparation of the drug.

ExcerptReference
" The bioavailability and pharmacokinetic and pharmacodynamic properties of oral nolatrexed were also studied."( Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days.
Boddy, AV; Calvert, AH; Calvete, JA; Clendeninn, N; Griffin, MJ; Hughes, AN; Johnston, A; Newell, DR; Rafi, I, 1999
)
" As oral bioavailability is high (70-100%), nolatrexed was administered orally, 6 hourly for 10 days, at 3-week intervals, and dose escalated from 80 to 572 mg m(-2) day(-1) in 23 patients."( A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
Boddy, A; Bowman, A; Byrne, B; Clendeninn, NJ; Jodrell, DI; Johnston, A; Rafi, I; Rye, R; Taylor, GA, 1999
)
"To establish a methods based on high-performance liquid chromatogram-mass spectrum for measuring the plasma concentration of nolatrexed dihydrochloride and investigate the pharmacokinetic profile and absolute bioavailability of the drug in mice."( [Measurement of plasma concentration and bioavailability of nolatrexed dihydrochloride in mice].
Shao, CF; Wan, SH; Wang, GF; Wu, SY; Xu, W; Zhang, JJ; Zhang, JY, 2008
)
" The pharmacokinetic parameters were calculated using DAS software, and the absolute bioavailability of orally and intravenously administered was assessed according to the ratio of their area under the curve (AUC)."( [Measurement of plasma concentration and bioavailability of nolatrexed dihydrochloride in mice].
Shao, CF; Wan, SH; Wang, GF; Wu, SY; Xu, W; Zhang, JJ; Zhang, JY, 2008
)
" The absolute bioavailability of nolatrexed dihydrochloride in mice was 23."( [Measurement of plasma concentration and bioavailability of nolatrexed dihydrochloride in mice].
Shao, CF; Wan, SH; Wang, GF; Wu, SY; Xu, W; Zhang, JJ; Zhang, JY, 2008
)
"The absolute bioavailability of nolatrexed dihydrochloride in mice determined in this study provides an experimental basis for development of the oral preparation of the drug."( [Measurement of plasma concentration and bioavailability of nolatrexed dihydrochloride in mice].
Shao, CF; Wan, SH; Wang, GF; Wu, SY; Xu, W; Zhang, JJ; Zhang, JY, 2008
)
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)

Dosage Studied

ExcerptReference
" Prolonged dosing periods of 5 or 10 days were required for activity, and efficacy was improved with twice-daily dose administration."( AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies.
Bartlett, CA; Boritzki, TJ; Hillard, JA; Howland, EF; Johnston, AL; Kosa, M; Margosiak, SA; Morse, CA; Shetty, BV; Webber, S, 1996
)
" Nolatrexed plasma concentrations 1 h after dosing were 6-16 microg ml(-1), and trough 3-8 microg ml(-1), at 572 mg m(-2) day(-1)."( A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
Boddy, A; Bowman, A; Byrne, B; Clendeninn, NJ; Jodrell, DI; Johnston, A; Rafi, I; Rye, R; Taylor, GA, 1999
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.84870.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency0.75640.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency10.68400.00108.379861.1304AID1645840
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency5.90360.035520.977089.1251AID504332; AID588344
gemininHomo sapiens (human)Potency15.60720.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency6.85420.005612.367736.1254AID624032; AID624044
Interferon betaHomo sapiens (human)Potency0.75640.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.75640.01238.964839.8107AID1645842
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency19.95260.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.75640.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.75640.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidylate synthase Escherichia coliKi0.09450.00300.06870.1500AID211629; AID211630
Thymidylate synthaseHomo sapiens (human)Ki0.01550.00010.34353.0000AID221977; AID221978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (66)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
dTMP biosynthetic processThymidylate synthaseHomo sapiens (human)
dTTP biosynthetic processThymidylate synthaseHomo sapiens (human)
circadian rhythmThymidylate synthaseHomo sapiens (human)
response to xenobiotic stimulusThymidylate synthaseHomo sapiens (human)
response to toxic substanceThymidylate synthaseHomo sapiens (human)
negative regulation of translationThymidylate synthaseHomo sapiens (human)
uracil metabolic processThymidylate synthaseHomo sapiens (human)
methylationThymidylate synthaseHomo sapiens (human)
response to progesteroneThymidylate synthaseHomo sapiens (human)
response to vitamin AThymidylate synthaseHomo sapiens (human)
response to cytokineThymidylate synthaseHomo sapiens (human)
tetrahydrofolate interconversionThymidylate synthaseHomo sapiens (human)
response to ethanolThymidylate synthaseHomo sapiens (human)
response to organophosphorusThymidylate synthaseHomo sapiens (human)
developmental growthThymidylate synthaseHomo sapiens (human)
cartilage developmentThymidylate synthaseHomo sapiens (human)
response to glucocorticoidThymidylate synthaseHomo sapiens (human)
response to folic acidThymidylate synthaseHomo sapiens (human)
intestinal epithelial cell maturationThymidylate synthaseHomo sapiens (human)
DNA biosynthetic processThymidylate synthaseHomo sapiens (human)
liver regenerationThymidylate synthaseHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
mRNA regulatory element binding translation repressor activityThymidylate synthaseHomo sapiens (human)
thymidylate synthase activityThymidylate synthaseHomo sapiens (human)
folic acid bindingThymidylate synthaseHomo sapiens (human)
protein homodimerization activityThymidylate synthaseHomo sapiens (human)
sequence-specific mRNA bindingThymidylate synthaseHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleusThymidylate synthaseHomo sapiens (human)
cytoplasmThymidylate synthaseHomo sapiens (human)
mitochondrionThymidylate synthaseHomo sapiens (human)
mitochondrial inner membraneThymidylate synthaseHomo sapiens (human)
mitochondrial matrixThymidylate synthaseHomo sapiens (human)
cytosolThymidylate synthaseHomo sapiens (human)
mitochondrionThymidylate synthaseHomo sapiens (human)
cytosolThymidylate synthaseHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID72895Inhibition of cellular growth in human adenocarcinoma cell line (GC3/M TK) deficient in thymidine kinase1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.
AID212469Relative potency to inhibit Thymidylate synthase in human, expressed as the ratio of IC50 of reference compound to that of the compound1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Synthesis of 5-substituted quinazolinone derivatives and their inhibitory activity in vitro.
AID211629Inhibition of purified Escherichia coli Thymidylate synthase1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.
AID221977Inhibition of human Thymidylate synthase1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.
AID44030Inhibition of human lymphoblastic leukemia (CCRF-CEM) cell growth measured using a modification of the MTT36 colorimetric assay of Mosmann1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.
AID211963Relative potency to inhibit Thymidylate synthase in Lactobacillus casei, expressed as the ratio of IC50 of reference compound to that of the compound1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Synthesis of 5-substituted quinazolinone derivatives and their inhibitory activity in vitro.
AID83932Concentration required to inhibit HT-29 (human colon adenocarcinoma) cell lines1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Synthesis of 5-substituted quinazolinone derivatives and their inhibitory activity in vitro.
AID221978Inhibition of human Thymidylate synthase1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.
AID96711Concentration required to inhibit L1210 (mouse lymphocytic leukemia) cell lines1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Synthesis of 5-substituted quinazolinone derivatives and their inhibitory activity in vitro.
AID211630Inhibition of purified Escherichia coli Thymidylate synthase1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.
AID21886Logarithm of partition coefficient was calculated1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.
AID44002Concentration required to inhibit CCRF-CEM (human leukemia) cell lines1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Synthesis of 5-substituted quinazolinone derivatives and their inhibitory activity in vitro.
AID98343Inhibition of mouse L1210 (murine leukemia) cell growth measured using a modification of the MTT36 colorimetric assay of Mosmann1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.
AID100312The ratio of IC50 of the inhibitor (assayed in L1210 cells) in presence and absence of thymidine1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.
AID99221Concentration required to inhibit LY3.7.2C TK-/-(mouse lymphoma, thymidine kinase deficient) cell lines1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Synthesis of 5-substituted quinazolinone derivatives and their inhibitory activity in vitro.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (58)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's25 (43.10)18.2507
2000's24 (41.38)29.6817
2010's6 (10.34)24.3611
2020's3 (5.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (21.67%)5.53%
Reviews6 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (68.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase III Randomized Controlled Study Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With THYMITAQ to Patients Treated With Doxorubicin[NCT00012324]Phase 30 participants Interventional2000-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]